Adlai Nortye shares jump 12.84% premarket after securing $140M private placement led by Cormorant, Columbia Threadneedle, and CEO investment.

Adlai Nortye Ltd. surged 12.84% in premarket trading following the announcement of a $140 million private placement led by top healthcare investors and CEO participation. The financing, selling 64.6 million Class A ordinary shares at $2.1667 each, includes $55 million in shares purchased by entities controlled by Chairman and CEO Yang Lu. The company emphasized investor confidence in its RAS-targeting therapies and next-generation cancer immunotherapies, with proceeds intended to advance its pipeline of drug candidates. The involvement of high-profile institutional investors and insider funding underscores strong support for Adlai Nortye’s strategic focus on transformative cancer treatments, directly aligning with the stock’s sharp premarket increase.